MAP Pharmaceuticals, Inc. (MAPP) has 41 open-market insider trades by 22 insiders since 2007. The most active filer is Capital L.l.c. FirstMark.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Carl Goldfischer | Dir | — | 2 | $9.6M | 2010-03-16 |
| Matthew V. McPherron | Dir | — | 1 | $7.2M | 2013-03-01 |
| Capital Investors L. P. Brookside | 10% | — | 1 | $7.2M | 2007-10-11 |
| Capital L.l.c. FirstMark | — | — | 14 | $6.7M | 2009-07-15 |
| City Capital Fund Iv L.p. Bay | 10% | — | 1 | $5.4M | 2010-03-11 |
| John Gordon Freund | Dir10% | — | 2 | $3.0M | 2011-05-20 |
| Jonathan T. Allan Soros | 10% | — | 1 | $2.9M | 2010-03-05 |
| Participation Lp Sfm | 10% | — | 2 | $2.6M | 2010-03-05 |
| Frank H. Pearl | 10% | — | 1 | $2.1M | 2010-05-11 |
| SOROS FUND Management LLC | 10% | — | 1 | $1.5M | 2010-03-09 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Geraldine Henwood | Director | Sell | $250K | 2013-02-28 |
| Anastasios Gianakakos | SVP & Chief Business Officer | Sell | $500K | 2013-02-28 |
| Donald J. Kellerman | SVP & Clinical Dev & Med Affairs | Sell | $35K | 2013-02-01 |
| Scott Borland | SVP & Neurology Franchise | Sell | $19K | 2013-01-26 |
| Anastasios Gianakakos | SVP & Chief Business Officer | Sell | $743K | 2013-01-23 |
| Thomas A. Armer | Chief Scientific Officer | Sell |
Companies that share insiders with MAPP, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| $1.5M |
| 2013-01-23 |
| Timothy S. Nelson | President | Sell | $2.0M | 2013-01-23 |
| Geraldine Henwood | Director | Sell | $79K | 2012-11-23 |
| Anastasios Gianakakos | SVP & Chief Business Officer | Sell | $90K | 2012-11-01 |
| Anastasios Gianakakos | SVP & Chief Business Officer | Sell | $36K | 2012-04-02 |
| Anastasios Gianakakos | SVP & Chief Business Officer | Sell | $175K | 2012-03-09 |
| Anastasios Gianakakos | SVP & Chief Business Officer | Sell | $40K | 2012-02-21 |
| Thomas A. Armer | Chief Scientific Officer | Sell | $529K | 2012-02-13 |
| Thomas A. Armer | Chief Scientific Officer | Sell | $419K | 2012-02-08 |
| Anastasios Gianakakos | SVP & Chief Business Officer | Sell | $150K | 2012-02-06 |